Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

Rhea-AI Summary

Innovent Biologics, Inc. announces the presentation of preclinical data on multiple novel bispecific antibodies and antibody-drug-conjugates from its oncology pipeline at the AACR Annual Meeting 2024. The company aims to develop next-generation therapies to tackle drug resistance and enhance treatment outcomes in immunotherapy.

ROCKVILLE, Md. and SUZHOU, China, March 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024. The AACR meeting will take place April 5-10, 2024, in San Diego, California.

Late-Breaking Research: Experimental and Molecular Therapeutics 1
Topic: IBI3001: a potentially first-in-class site-specifically conjugated B7-H3/EGFR bispecific ADC for multiple solid tumors
Abstract Number: LB055
Presentation Form: Poster
Presentation Time：Sunday Apr 7, 2024 1:30 PM - 5:00 PM
Location: Poster Section 53
Presenting Author: Dr. Kaijie He

Topic: IBI334, a novel ADCC-enhanced B7-H3/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors
Abstract Number: LB056
Presentation Form: Poster
Presentation Time：Sunday Apr 7, 2024 1:30 PM - 5:00 PM
Location: Poster Section 53
Presenting Author: Dr. Kaijie He

Topic: Discovery and preclinical characterization of IBI343, a site-specifically conjugated anti-Claudin18.2 ADC for treating solid tumors
Abstract Number: LB057
Presentation Form: Poster
Presentation Time：Sunday Apr 7, 2024 1:30 PM - 5:00 PM
Location: Poster Section 53
Presenting Author: Dr. Kaijie He

Poster Session: Immunology - Single Target and Bispecific Antibodies
Topic: A novel TROP2-targeted immune stimulating antibody conjugate (ISAC) with potent anti-tumoral activity and acceptable safety
Abstract Number: 2718
Presentation Form: Poster
Presentation Time: Monday Apr 8, 2024 1:30 PM - 5:00 PM
Location: Poster Section 6
Poster Board Number: 9
Presenting Author: Dr. Huizhong Xiong

Poster Session: Immunology - Immune Modulation Employing Agonist or Co-Stimulatory Approaches
Topic: Tumor targeted-CD28 bispecific antibody with optimized potency, robust anti-tumoral activity and stringent CD3-dependence
Abstract Number: 5295
Presentation Form: Poster
Presentation Time: Tuesday Apr 9, 2024 1:30 PM - 5:00 PM
Location: Poster Section 3
Poster Board Number: 4
Presenting Author: Dr. Huizhong Xiong

Dr. Kaijie He, Vice President of Innovent, stated: "We aim to tackle drug resistance and enhance treatment outcomes in immunotherapy by developing next-generation bispecific antibodies, multi-specific antibodies and ADCs candidates. To select targets that can address broad-spectrum of tumor types is one of our main research direction. We are pleased to present preclinical data of innovative molecules at the AACR and accepted as Late-breaking Researches. We hope to benefit more patients with continuous advances in life science and technology. " 

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable illnesses. Its pioneering therapies to treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 4 assets in Phase III or pivotal clinical trials and 20 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Note:
TYVYT^® (sintilimab injection), BYVASDA^® (bevacizumab biosimilar injection), SULINNO^®, and HALPRYZA^® (rituximab biosimilar injection) are not approved products in the United States.
TYVYT^® (sintilimab injection, Innovent)
BYVASDA^® (bevacizumab biosimilar injection, Innovent)
HALPRYZA^® (rituximab biosimilar injection, Innovent)
SULINNO^® (adalimumab biosimilar injection, Innovent)
Pemazyre^® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre^® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.
CYRAMZA^® (ramucirumab, Eli Lilly). Cyramza^® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.
Retsevmo^® (selpercatinib, Eli Lilly). Retsevmo^® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.

Disclaimer: Innovent does not recommend any off-label usage.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

View original content:https://www.prnewswire.com/news-releases/innovent-to-present-preclinical-data-of-multiple-novel-molecules-at-the-2024-aacr-annual-meeting-302085392.html

SOURCE Innovent Biologics

FAQ

What is the event where Innovent Biologics will present preclinical data on novel bispecific antibodies and ADCs?

Innovent Biologics will present preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2024.

What is the abstract number for the potentially first-in-class site-specifically conjugated B7-H3/EGFR bispecific ADC for multiple solid tumors?

The abstract number is LB055 for the potentially first-in-class site-specifically conjugated B7-H3/EGFR bispecific ADC.

Who is the presenting author for the novel ADCC-enhanced B7-H3/EGFR bispecific antibody?

Dr. Kaijie He is the presenting author for the novel ADCC-enhanced B7-H3/EGFR bispecific antibody.

What is the main research direction mentioned by Dr. Kaijie He, Vice President of Innovent?

Dr. Kaijie He mentioned that the main research direction is to select targets that can address a broad spectrum of tumor types.